LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on telehealth infrastructure and healthcare analytics for emerging markets, announced plans to submit a corporate action request to FINRA for a five-for-one (5-for-1) forward stock split. The proposal includes proportional increases in the company's authorized common and preferred stock, including its Series C Voting Preferred Stock.
The forward stock split is intended to support broader long-term operational scalability, strategic flexibility, capitalization planning, and future growth initiatives as LataMed advances telehealth infrastructure deployment, healthcare analytics integration, regulatory progression, and commercialization throughout Latin America and other targeted emerging markets. The company emphasized that the proposed action does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected, as any fractional interests would be rounded up to the nearest whole share.
Management stated that the stock split aligns with the company's transition into digital healthcare infrastructure and AI-driven telehealth operations. Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., said, “As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.”
The announcement follows the recent commencement of initial operational activities for LataMed's telehealth platform in Venezuela, following regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). The proposed forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the action.
LataMed AI Corp. is a development-stage company that has not generated revenues from its current business operations. It is building a technology-enabled healthcare ecosystem designed to support remote patient engagement, provider coordination, healthcare analytics, and broader digital healthcare delivery in emerging markets. The company is positioning itself to participate in the modernization of healthcare delivery systems across these regions through telehealth infrastructure, AI-driven technologies, regulatory progress, and strategic partnerships.
For more information, visit https://latamed.ai, follow the Company’s official Instagram page at https://www.instagram.com/latamedai, or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
